What is Schrödinger, Inc.'s (SDGR) StockRank?

MoatMap's StockRank for Schrödinger, Inc. (SDGR) is 15/100, with a Strong Sell signal. This is a composite score combining Quality (33), Value (28), and Momentum (36) factor ranks across MoatMap's 20,000+ stock universe.

Does Schrödinger, Inc. have an economic moat?

Schrödinger, Inc. (SDGR) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Schrödinger, Inc. a buy, hold, or sell?

MoatMap's current signal for Schrödinger, Inc. (SDGR) is Strong Sell, based on a StockRank of 15/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Schrödinger, Inc. in?

Schrödinger, Inc. (SDGR) operates in the Healthcare sector, specifically the Health Information Services industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

SDGR

STRONG SELLREMOVE

Schrödinger, Inc. · Healthcare · United States · $1.1B · Avg Vol: $20M/d

StockRank

P/E (TTM)

—

ROE

-30.1%

D/E

0.3x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Schrödinger provides valuable physics-based software for drug discovery, but its business model is split between low-margin drug discovery collaboration bets and software licensing. It lacks the predictable, high-ROIC compounding profile we require.

COMPANY DESCRIPTION

Schrödinger, Inc. offers a physics-based computational platform that accelerates drug discovery and materials science research by enabling the prediction of molecular properties with high accuracy. The company's competitive advantage lies in its proprietary, industry-leading simulation software and deep scientific expertise, establishing it as a critical technology partner for pharmaceutical and biotech innovators.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	181.0M	216.7M	207.5M	255.9M	12.2%
EPS	-2.10	0.57	-2.57	-1.41	—
Shares	71.3M	72.1M	72.9M	73.7M	+3.3%
Debt	116.5M	127.9M	117.8M	109.2M	-2.1%
Equity	447.9M	548.6M	421.4M	364.1M	-6.7%
Op CF	-119.7M	-136.7M	-157.4M	13.9M	—
Inv CF	90.0M	193.0M	148.8M	57.9M	—
Fin CF	2.1M	9.0M	10.1M	2.9M	—

PRICE (1Y)+16.0%

SMA 50SMA 200

$15.23

RSI (14)

45.4

52W High

$23.75

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

-31.1%22.3

ROE

-30.1%25.1

GP/Assets

19.4%45.4

Op. Margin

-83.3%17.9

FCF/Assets

-6.8%32.7

Piotroski

430.3

Int. Cover

—N/A

D/E Ratio

0.34x40.6

Current Ratio

2.74x49.7

Value

P/E (TTM)

—N/A

EV/EBITDA

-5.6x25.0

P/FCF

—N/A

P/B

3.7x34.9

P/S

4.6x43.8

Div Yield

—N/A

Momentum

52W High %

64%50.6

RS 6M

-24%53.0

SMA 50/200

0.84x18.7

EPS Rev 4W

0.0%49.2

EPS Rev 12W

-13.4%15.9

EPS Improve

-12%16.4

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$1.1B

P/E (Forward)

-10.0x

Gross Margin

55.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SDGR are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
SDGR	Schrödinger, Inc.(you)	$1.1B	15	STRONG SELL
CARL	Carlsmed, Inc.	$264M	18	STRONG SELL
EVH	Evolent Health, Inc.	$486M	32	SELL
OMDA	Omada Health, Inc.	$1.1B	48	HOLD
CERT	Certara, Inc.	$850M	46	HOLD
PHR	Phreesia, Inc.	$564M	41	HOLD
CTEV	Claritev Corporation	$491M	39	HOLD
TEM	Tempus AI, Inc.	$8.7B	11	STRONG SELL
WEAV	Weave Communications, Inc.	$406M	39	HOLD
HTFL	Heartflow, Inc.	$3.0B	42	HOLD

Peer medians: ROE -22.7% · P/E 25.2x · Gross margin 44.3%

Schrödinger, Inc. (SDGR) — Stock Score Summary

Schrödinger, Inc. (SDGR) has a MoatMap StockRank of 15/100 based on Quality (33/100), Value (28/100), and Momentum (36/100) factor scores. The current signal is STRONG SELL. Schrödinger provides valuable physics-based software for drug discovery, but its business model is split between low-margin drug discovery collaboration bets and software licensing. It lacks the predictable, high-ROIC compounding profile we require.

Key Financial Metrics

Price	$15.23
Market Cap	$1.1B
P/E (Forward)	-9.96
Price/Book	3.70
Return on Equity	-30.1%
Return on Invested Capital	-31.1%
Debt/Equity	34.13
Gross Margin	55.3%
Operating Margin	-83.3%
Revenue Growth	-1.6%
Free Cash Flow	$-49M

Schrödinger, Inc. operates in the Health Information Services industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Schrödinger, Inc.’s (SDGR) StockRank?: MoatMap’s StockRank for Schrödinger, Inc. (SDGR) is 15/100, with a Strong Sell signal. It is a composite of Quality (33), Value (28), and Momentum (36) factor ranks across MoatMap’s 20,000+ stock universe.
Does Schrödinger, Inc. have an economic moat?: Schrödinger, Inc. (SDGR) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Schrödinger, Inc. a buy, hold, or sell?: MoatMap’s current signal for Schrödinger, Inc. (SDGR) is Strong Sell, based on a StockRank of 15/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Schrödinger, Inc. in?: Schrödinger, Inc. (SDGR) operates in the Healthcare sector, specifically the Health Information Services industry (United States).